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Analgesic use and chronic renal failure: A critical review of the
epidemiologic literature. Heavy use of analgesics, particularly
over-the-counter (OTC) products, has long been associated with
chronic renal failure. Most of the earlier reports implicated
phenacetin-containing analgesics as the risk factor. Since the early
1980s, several case-control studies have reported associations
between chronic renal failure and use of other forms of analgesics,
including acetaminophen, aspirin, and other non-steroidal anti-
inflammatory drugs (NSAIDs). Findings from these studies, how-
ever, should be interpreted with caution because of a number of
inherent limitations and potential biases in the study design and
data collection procedures. These limitations include: failure to
identify patients early enough in the natural history of their
disease to collect reliable information on analgesic use at an
etiologically relevant time period; selection bias due to incomplete
identification of subjects or low response rates; selection of cases
and controls from different population bases; failure to employ
survey techniques to improve reliability of recall of analgesic use;
failure to collect detailed information on analgesic use such as
year started and ended and reasons for switching analgesics; lack
of standardization in the definition of regular analgesic use; and
failure to adjust for phenacetin use and other confounding factors
when assessing associations with analgesics other than those
containing phenacetin. It is our hope that this review of study
design limitations will lead to improvements in future studies of
chronic renal failure risk. Since use of analgesics is widespread
and new OTC products are introduced frequently, the potential
impact of these drugs on the development of chronic renal failure
may be significant, thus warranting continued evaluation of these
products for any renal toxicity.
Abuse of analgesics has long been associated with the
development of chronic renal failure. The clinically well-
defined entity of classic analgesic nephropathy is a slowly
progressing disease resulting from the daily consumption
over several years of mixtures containing at least two
antipyretic analgesics, usually combined with caffeine
and/or codeine, both creating a psychological dependence.
It is characterized by renal papillary necrosis and chronic
interstitial nephritis [1, 2], which once established tend to
progress to end-stage renal disease (ESRD). Efforts to halt
or even slow the progression have for the most part been
unsuccessful [3, 4]. The incidence of ESRD and expendi-
tures related to its treatment have been increasing consis-
tently in the United States [5]; in 1989, an estimated
200,000 persons received treatment for ESRD and the
direct costs of such therapy amounted to $6 billion [5]. The
progressive nature of chronic renal disease and the high
costs of its treatment underscore the importance of identi-
fying preventable causes of this disease. In particular, given
the extensive worldwide market for analgesics and the
general acceptance of their safety, detailed evaluation of
the potential renal toxicity of these drugs is warranted.
Since the association between abuse or long-term heavy
use of analgesics and chronic interstitial nephritis was first
recognized more than four decades ago [6], numerous cases
of analgesic-associated nephropathy have been docu-
mented [7], but a causal association has not been conclu-
sively established. The majority of reports have implicated
heavy consumption of analgesic mixtures containing phen-
acetin as the responsible agent [7–10]. By the late 1960s
phenacetin was removed from the market in Scandinavia
and by the 1970s was subsequently removed in many
industrialized countries [7, 11]. In the United States, all
phenacetin preparations were required after 1964 to bear a
warning about possible kidney damage [12], and the drug
was banned from the market in 1983 [13].
Several large analytic epidemiologic studies have more
recently raised concern that chronic renal failure may be
linked to heavy use of not only phenacetin, but also of a
number of commonly used analgesics such as aspirin, other
non-steroidal anti-inflammatory drugs (NSAIDs), and acet-
aminophen [14–16]. In the United States, NSAID prescrip-
tions increased rapidly from 27.5 million in 1973 to 66.7
million in 1983, although use of prescribed NSAIDs has
stabilized since then. This phenomenon may be explained
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in part by the increased awareness among physicians of the
gastrointestinal side effects of excessive NSAID use, as well
as by approval of various NSAIDs for over-the-counter
(OTC) sales [17, 18]. Since the 1980s, the stagnant market
share of prescription NSAIDs has been replaced by in-
creasing sales of acetaminophen and of former prescrip-
tion-only NSAIDs such as ibuprofen, which now account
for about one third of the OTC analgesic market share. As
early as 1980, aspirin substitutes (primarily acetaminophen)
accounted for $300 million of the then $1.2 billion spent on
analgesic medication in the United States [19].
Of the OTC analgesics, acetaminophen has generated
the greatest concern with respect to renal disease because
it is the major metabolite of phenacetin [20, 21], although
not the only metabolite [22, 23], and because acetamino-
phen-induced renal necrosis has been observed in suscep-
tible laboratory animals [24–27]. However, the collective
epidemiologic evidence with respect to acetaminophen as a
single product is inconclusive. The majority of reports of
chronic renal disease associated with acetaminophen use
have been case series [7, 28, 29].
Most of the analytic epidemiologic data on analgesic use
and chronic renal failure are derived from case-control
studies [9, 14–16, 30–33]. To our knowledge, only two
cohort studies [34, 35] have linked analgesic use to elevated
risk of chronic renal failure, with similar risk estimates.
Elseviers and De Broe [35] reported a significant sixfold
increase in risk of decreased renal function among abusers
of any type of analgesic compared to controls; their esti-
mate, however, was based on only 12 exposed cases. In the
10-year follow-up study by Dubach, Rosner and Pfister [34],
heavy use by young women of phenacetin-containing prod-
ucts was associated with an eightfold increased risk of
developing renal failure, as measured by serum creatinine
levels, but the absolute incidence of abnormal kidney
function remained relatively small even among heavy users.
Increased risk of mortality from urologic or renal disease
was also reported in this study among heavy users of
phenacetin [36]. Another small cohort study demonstrated
a nonsignificant positive association between high analgesic
use and papillary calcification [21]. By contrast, increased
risks associated with acetaminophen use have been re-
ported in several [15, 16, 30, 31], but not all [9], case-control
studies of chronic renal disease, with aspirin and other
NSAIDs often implicated as well [14–16, 31, 32].
Inherent methodologic limitations and potential biases
in study design and data collection, however, hamper the
interpretation of associations between analgesic use and
chronic renal failure or ESRD observed in case-control
studies. The purpose of this review is to critically evaluate
the existing epidemiologic evidence that use of analgesics
may increase the risk of chronic renal failure, and to
suggest methods for improving the design of future studies
of this issue.
CASE-CONTROL STUDIES OF ANALGESIC USE AND
CHRONIC RENAL DISEASE
To date, the results of at least seven case-control studies
of chronic renal failure have been reported in the United
States and Europe (Table 1). All but one [33] were
designed specifically to evaluate the role of analgesic use,
but the studies varied according to case and control selec-
tion criteria, definition of analgesic use, and method of data
collection. Many were based on relatively small numbers of
users of large amounts of analgesics, making it difficult to
meaningfully evaluate the role of these drugs in the etiology
of renal failure. In one study, for instance, only 1.2% of
controls and 0.6% of patients ever used acetaminophen in
a single ingredient product [30]. The characteristics of
these studies, as summarized in Table 1, will be reviewed
below, with particular attention to methodologic strengths
and weaknesses that could influence the interpretation of
results.
Case identification and selection
The diagnostic criteria for defining cases of chronic renal
disease varied across studies. In fact, only two studies [9,
15] have specified objective diagnostic criteria, and in the
remaining studies it is difficult to rule out subjective
diagnosis by physicians who were aware of the patients’
analgesic use history. Moreover, most studies enrolled
patients undergoing dialysis for ESRD, most likely as a
result of the difficulty of diagnosing renal disease during
the early stages. Thus, a critical limitation is the failure to
identify and recruit chronic renal failure patients early
enough in the natural course of their disease to insure that
analgesic exposure information pertains to an etiologically
relevant period prior to the development of the disease.
Only in the study by Sandler et al [14, 15] were cases
patients with kidney disease newly diagnosed based on
serum creatinine levels. In the other six studies, cases were
patients drawn from hemodialysis or renal transplant cen-
ters [30–32], registries of patients with ESRD [16, 33], or
outpatient clinics [9]. Once diagnosed with chronic renal
insufficiency, patients are often advised to discontinue use
of aspirin and other NSAIDs as these drugs increase the
risk of bleeding, interfere with renal potassium excretion
and may further compromise their glomerular filtration
rate [37–39]. As an alternative, these patients are often
advised to use acetaminophen for pain relief following their
diagnosis.
Patients with ESRD or those identified from hemodial-
ysis units are likely to be prevalent cases in the final stages
of their illness; they do not necessarily represent the
population with non-terminal kidney disease in terms of
patterns of analgesic use. It is the incidence of chronic renal
failure, rather than the prevalence of ESRD, that is the
more etiologically relevant outcome, since studies based on
prevalent cases yield associations that may reflect determi-
nants of duration and course of disease as much as the
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Table 1. Case-control studies of analgesic use and chronic renal failure
Author,
Year Location
Study
period Study population
Data
collection Analgesic Data Results
Murray
et al.,
198331
Pennsylvania
New
Jersey
10/78–
8/79
527 ESRD1 patients
in dialysis units;
1,047 matched
hospital controls
Personal
interview
Life history of conditions likely to
be treated with analgesics;
Review of list of analgesics in
use from 1920 to 1979; Detailed
history for analgesics used daily
or every other day for 30 days
or more
No consistent association with ever
use, duration of use or dose of
aspirin, acetaminophen or
phenacetin, alone or in
combination products; Compared
to nonusers of any analgesic: RR 5
2.55 (1.07–6.11) for $3 years of
phenacetin use; RR 5 4.59 (1.59–
13.28), 0.33 (0.10–1.07), and 2.00
(0.59–6.74) for ,1 year, 1–,3
years, and $3 years of
acetaminophen use, respectively
McCredie
and
Stewart,
19889
Australia 1978–
1980
91 cases of renal
papillary necrosis
from outpatient
clinics; 120 clinic
controls with other
kidney diseases
Personal
interview
Lifetime consumption of
analgesics up to the year of
diagnosis
Compared to ,1 kg: OR 5 19 (10–
37) for $1 kg phenacetin; OR 5
0.5 (0.1–1.9) for $1 kg
paracetamol
Compared to ,0.1 kg: OR 5 15
(8–28) for $0.1 kg phenacetin;
OR 5 0.7 (0.3–1.9) for $0.1 kg
paracetamol4
Sandler
et al.,
1989,
199114,15
North
Carolina
9/80–
8/82
554 patients newly
diagnosed with
CRF2 and with
serum creatinine
levels consistently
$130 mmol/liter;
516 population-
based controls,
identified through
random digit dialing
or Social Security
lists
Telephone
interview
Life history of conditions likely to
be treated with analgesics;
Review of lists of generic and
brand-name analgesics, sold
OTC or by prescription in the
1960s and 1970s according to
North Carolina pharmacy
survey; Detailed history for
analgesics used 10 or more
times
Compared to infrequent use: OR for
daily use of any analgesic 5 2.79
(1.85–4.21), for phenacetin-
containing analgesic 5 5.11 (1.70–
14.9), for acetaminophen 5 3.21
(1.05–9.80), for aspirin 5 1.32
(0.69–2.51); OR for daily use of
NSAIDS 5 4.6 (1.5–14.0) in men
and 1.1 (0.4–2.7) in women, with
increased risk in men restricted to
men .65 years of age4
Pommer
et al.,
198932
Germany 1984–
10/86
517 ESRD1 patients
in dialysis units or
undergoing renal
replacement
therapy; 517
matched clinic
controls
Personal
interview
Detailed history among regular
users, defined as users of 15 or
more doses per month for one
year or longer
Compared to no regular intake: RR
for regular intake of any analgesic
5 2.44 (1.77–3.39); RR for regular
intake of combination drugs 5
2.65 (1.91–3.67); RR 5 9.20
(2.06–39.87) for .1 kg phenacetin
in lifetime; RR 5 4.06
(1.32–12.43) for .1 kg
acetaminophen in lifetime
Morlans
et al.,
199033
Spain 9/80–
9/83
340 ESRD1 patients
in dialysis units; 673
matched hospital
controls
Personal
interview
Life history of conditions likely to
be treated with analgesics; List
of analgesics by brand names
and sample packages; Detailed
history for analgesics used daily
or every other day for 30 days
or more; No assessment of
acetaminophen
No assessment of acetaminophen;
OR 5 2.89 (1.78–4.68) for regular
use of analgesics; OR 5 19.05
(2.31–157.4) for regular use of
phenacetin; OR 5 2.54
(1.24–5.20) for regular use of
salicylates4
Steenland
et al.,
199035
Michigan 1976–
1984
325 ESRD1 patients
identified from a
registry; 325
matched population-
based controls,
identified through
random digit dialing
Telephone
interview
Regular pain pill use defined as
more than one pill per week for
two years or more;
Acetaminophen grouped with
phenacetin
OR for phenacetin/acetaminophen
use 5 2.66 (1.04–6.82); trend of
increasing risk with increasing
duration of use
Perneger
et al.,
199416
Maryland
Virginia
West
Virginia
Washington,
DC
1/91–
7/91
716 ESRD1 patients
identified from a
registry; 361
population-based
controls identified
through random
digit dialing
Telephone
interview
Lifetime exposure to 5 groups of
analgesics; Review of lists of
brand-name NSAIDs3,
according to 1990 Baltimore
pharmacy survey; Review of
lists of non-NSAID3 analgesics,
according to North Carolina
pharmacy survey (Sandler et al.
1989); Detailed history of use
for analgesics taken 10 or more
times in a lifetime
Compared to average intake of 0–104
pills/year: OR for intake of 105–
365 pills/year 5 1.4 (0.8–2.4) for
acetaminophen, 0.8 (0.5–1.3) for
aspirin, 0.8 (0.4–1.5) for NSAIDs;
OR for intake $366 pills/year 5
2.1 (1.1–3.7) for acetaminophen,
1.1 (0.7–1.9) for aspirin, 1.0 (0.5–
2.0) for NSAIDs4
1 ESRD: end-stage renal disease
2 CRF: chronic renal failure
3 NSAID: non-steroidal anti-inflammatory drug
4 mutual adjustment among types of analgesics
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causes of disease. Thus, whether cases come from selected
facilities or from a defined population, they should be
limited to those newly diagnosed within a specified time
period. Additional selection biases may be introduced when
registries of patients with ESRD are used as a source for
case identification, if case registration is incomplete or
reporting of cases to the registry is selective [16, 33]. For
instance, among cases identified from the Mid-Atlantic
Renal Coalition in the study by Perneger, Whelton and
Klag [16], 54% were blacks. Analyses of the data as
presented would indicate that blacks have a sevenfold
increased risk for ESRD compared with whites, a relative
risk that is clearly overestimated based on the descriptive
epidemiology of the disease. The substantially higher per-
centage of blacks suggests differential referral and registra-
tion by race. When cases are recruited only from selected
area clinics and dialysis units or, alternatively, when pa-
tients referred from outside the study area are not excluded
from the study, the primary study base that gave rise to the
cases, and therefore the comparability of controls, is diffi-
cult to define. Finally, the representativeness of the case
population may be limited by a low response rate or
selective non-response among patients. In one study [33],
for instance, only 53% of the eligible cases identified from
a registry were eventually interviewed, and the non-respon-
dents were more likely to be black and living in inner cities
than study participants. In another study [15], white pa-
tients again were more likely than black patients to partic-
ipate. The true relationship between analgesic use and
chronic renal failure could be distorted in these studies if
non-response is selective with respect to exposure, that is, if
black patients or those living in inner cities have unusually
high or low use of analgesics.
Control identification and selection
In order to have valid comparisons between groups in
case-control studies, controls must be drawn from the same
source population that gave rise to the cases [40]. Patients
identified from population-based registries or from all
clinics serving a well-defined geographic area [14–16, 33]
should be compared with controls selected from the same
general populations from which those cases were drawn. A
number of investigations of analgesic use and renal disease
have violated this fundamental epidemiologic principle,
and comparability between cases and controls is therefore
questionable. For instance, in a study conducted in the
Mid-Atlantic region of the United States [16], the majority
of the cases were male (58%) and black (54%), while the
controls were predominantly female (65%) and white
(86%). The overrepresentation of females among controls
identified through random digit dialing suggests a selection
bias with respect to socioeconomic status, whereby women
more likely to be at home (housewives) are more likely to
be selected. In another study [15], cases were significantly
poorer and less educated than controls. Since patterns of
analgesic use vary substantially by demographic character-
istics [41, 42], only an appropriately stratified analysis
controlling for the selection factors (that is, race, gender,
socioeconomic status) will eliminate the associated selec-
tion bias for all other variables, including analgesic use. In
general, a selection bias will be introduced when controls
are chosen through a process that is associated with the
exposure under consideration, in this case analgesic use.
Controlling for the suspected selection factors in the anal-
ysis of the data may reduce (but not necessarily eliminate)
this problem, provided the selection factors can be correctly
identified and accurately measured. In most studies, how-
ever, these factors were not appropriately identified or
controlled for in the analysis (see below).
For the studies in which cases were identified from
certain clinics or dialysis units, the controls have been
selected from among patients treated for other conditions
in the same hospitals or clinics or from those treated at
different hospitals near the residence of the patient [30,
32]. Under such circumstances, the comparability of the
two groups can be ensured only if the catchment area for
the different hospitals and clinics is the same and patients
residing outside the catchment area are excluded [40],
criteria that clearly are not fulfilled in several studies.
Moreover, hospital controls with conditions requiring ex-
tensive pain relief should be excluded since their patterns
of analgesic use do not represent the exposure distribution
in the source population for the cases. In fact, hospital
patients in general are believed to have atypical patterns of
analgesic use. In one study [30], approximately 40% of
controls had either gastrointestinal tract, musculoskeletal
and joint, urinary tract or neurologic disease, most of which
may have been associated with or caused by analgesic
consumption. A higher analgesic use among these controls
compared to the source population would tend to bias the
effect estimates to the null, and could explain in part the
lack of association between analgesics and ESRD in this
study. An additional selection bias may be introduced as a
result of the low response rates among controls in a number
of case-control studies [30, 33].
It is of interest that to date, only one study has under-
taken analytic procedures to increase confidence in the
comparability of the case and control series [32]. This can
be done by: (a) comparing cases and controls with respect
to the frequency of reporting of exposures or characteristics
unlikely to be relevant to the etiology of the study disease;
or (b) examining a group of patients not expected to share
the etiologic background of the true cases, although they
went through the same study procedures as the cases.
Morlans et al evaluated 41 patients with ESRD caused by
cystic kidney disease, a congenital condition, and found no
association with analgesic use [32]; this finding serves to
increase our confidence in the validity of the associations
found with non-congenital ESRD.
McLaughlin et al: Analgesic use and chronic renal failure682
Assessment of analgesic use
What is of particular concern in reviewing the relevant
studies is the enormous potential for information bias given
the various methods of assessing analgesic use, as well as
the different perceptions among cases and controls about
the problem under study. A complete history of analgesic
use, particularly OTC drug use, is difficult to obtain reliably
under the best of circumstances. It is especially doubtful
whether such drug exposures can be accurately assessed
through short telephone interviews or without visual recall
aids [14–16, 33]. In no study was self-reported analgesic
use, obtained through either telephone or in-person inter-
view, validated. Furthermore, only one case-control study
used photographs of the products and their packaging to
facilitate recall of analgesics used [32], despite the fact that
such visual aids have been shown to improve the reliability
of recall in other areas of survey research [43].
The structure of the questionnaire varied greatly across
studies and could have important consequences with re-
spect to the accuracy and completeness of information
elicited, and also to interpretation and comparison of
findings from different studies. For instance, the definition
of a regular user, for whom detailed history of analgesic use
was collected, ranged from more than one pill per week for
two or more years [33], to analgesics taken 10 or more
times in a lifetime [14–16], to users of 15 or more doses per
month for one year or longer [31], to use daily or every
other day for 30 days or more [30, 32]. Such diversity in the
definition of exposure and non-exposure may account for
the large discrepancies in percentages of “regular” analge-
sic users among controls, which ranged from 2% to 30% in
different studies. As a result, the magnitude of risk esti-
mates could be greatly affected and direct comparison of
findings from different studies is not possible.
The types of questions designed to elicit information on
past analgesic use and the methods used to enhance recall
also vary among studies. Investigators asked about history
of drug use prior to the start of hemodialysis or renal
transplantaton [16, 30, 31], prior to the appearance of
symptoms of kidney disease [32], up to the year of diagnosis
[9], or during the year before the start of the study [14, 15].
Even as such, the reference period for analgesic use was not
clearly defined and is likely to include more than the
relevant time window. The reference period is critically
important as an indication of when in the natural history of
the disease the analgesic exposure information is collected.
Given the removal of phenacetin from the market, the
more recent introduction of other types of analgesics, and
the documented changes in use patterns following disease
onset, it would also be useful to note the dates started and
ended for each type of analgesic and reasons for changes in
patterns of analgesic use. Unfortunately, only one study
provides this type of detailed information [31].
While failure to ensure that analgesic use preceded the
onset of kidney disease is not critical in assessing the role of
analgesics in the progression of established renal disease, it
becomes an important limitation in studies of the etiology
of the condition. The change in patterns of analgesic use
after the onset of renal disease may bias the recall and the
reporting of long-term analgesic use among ESRD pa-
tients, generating both false-positive (with respect to acet-
aminophen) and false-negative (with respect to aspirin)
errors that could significantly bias the effect estimates. The
potential for bias is further enhanced when the time
reference for analgesic use as specified in the questionnaire
is prior to starting dialysis; this approach would most likely
capture the most recent use pattern rather than use during
the etiologically significant time period long before the
onset of renal dialysis. Indeed, the reporting of analgesic
use patterns before the start of renal dialysis but after the
initial onset of the disease, when patients often abstain
from using aspirin, may account in part for the reduction in
risk associated with moderate use of aspirin and increase in
risk associated with acetaminophen use in at least one of
the case-control studies [16]. Even studies that attempt to
collect from prevalent cases data about analgesic use prior
to the onset of kidney disease [32] cannot guarantee that
the etiologically relevant time period is being reflected.
This is of particular concern given the variable and often
long time window between diagnosis and data collection for
prevalent cases, since reports by subjects on exposures in
the distant past tend to reflect the current exposure pattern
[43, 44].
In addition to asking direct questions about use patterns,
some [14, 15, 30, 32], but not all, investigators attempted to
enhance recall by asking about past medical conditions
likely to be treated with analgesics or providing a list of
analgesic products in use during certain time periods. This
type of probing, provided it was applied equally to both
cases and controls, may have generated more accurate and
complete data on analgesic use among study participants.
However, in the study by Pommer et al, interviewers were
not blinded with respect to case-control status, and non-
standardized probing intended to stimulate recall of anal-
gesic use could introduce information bias [31]. If in fact
cases were probed more than controls, this would lead to an
overestimation of the effect of analgesics on ESRD and
could explain the high relative risks observed in this study.
Finally, several investigators have addressed the issue of
underreporting by cases as a potential source of bias that
could attenuate risk estimates, and they have described
probing methods intended to minimize denial or underre-
porting of use. However, an equally important source of
bias that is often overlooked is the more likely problem of
overreporting by cases. Given the perceptions of patients
and physicians about the nephrotoxicity of analgesics,
overreporting by cases is likely and could lead to false
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positive associations, which could explain in part the in-
creased relative risks for analgesic use seen in several
studies.
A final issue encountered in some of these studies is the
collection of drug history and other information from
surrogate informants, rather than through direct interviews
with the patients or controls themselves, which raises
concern about the quality of the data as well as their
comparability to those obtained directly from living sub-
jects. While next-of-kin may provide reasonably reliable
data with respect to certain lifestyle factors, such as con-
sumption of tobacco, alcohol and coffee, their knowledge
regarding the subjects’ patterns of analgesic use, a relatively
private habit, may be less accurate [45, 46]. The potential
for bias appears to be greatest when data for one group,
such as cases, are obtained from surrogates, whereas data
for another, such as controls, are obtained from the index
subjects. The direction of information bias has not been
well-documented and might plausibly be in either a positive
or a negative direction. In one study [14, 15], data on
analgesic use were provided by next-of-kin respondents for
55% of the cases but only 10% of the controls, and a higher
level of analgesic use was consistently reported by next-of-
kin informants relative to self-respondents. It is possible
that the higher levels of analgesic use reported by surro-
gates compared to directly interviewed cases reflects a
survival bias whereby those patients who consume more
analgesics actually have shorter survival times. However, it
appears more likely that proxy respondents in general tend
to overreport subjects’ analgesic use, since an excess of
analgesic use was also reported by the proxy controls than
by directly interviewed controls. A number of other studies
[16, 30, 33], excluded cases who could not be interviewed
directly, due to either death or refusal. If cases who died of
chronic renal failure, however, were more or less likely to
be heavy, long-term users of analgesics than those cases
who survived, exclusion of deceased subjects may lead to an
underestimation or overestimation, respectively, of the
association of analgesic use with chronic renal failure.
DATA ANALYSIS AND INTERPRETATION
Failure to adequately adjust for the confounding effects
of phenacetin is a major limitation of most previous
case-control studies of acetaminophen and other analgesics
in relation to chronic renal disease. Phenacetin was widely
used in combination analgesics in the United States and
other countries from the early part of this century until the
1970s and even until the 1980s in some European countries.
In contrast, use of acetaminophen and some NSAIDs as
single analgesics did not become popular until the late
1970s to early 1980s. Thus, for most subjects identified
during the time period covered by the published studies,
the analgesic exposure of etiologic significance is primarily
phenacetin-containing products, and unadjusted positive
associations between ESRD and other analgesics are likely
to be overestimated due to confounding by earlier phenac-
etin use. For example, in the study conducted in North
Carolina [15], the numbers of cases (31) and controls (5)
who reported daily use of phenacetin were almost identical
to the numbers who reported daily use of acetaminophen
(30 cases and 5 controls), suggesting that they are the same
subjects. Moreover, with only 5 controls it is impossible to
adequately adjust for the effect of phenacetin or other
confounding factors in assessing the risk associated with
acetaminophen use. In order to meaningfully evaluate the
association between acetaminophen and chronic renal fail-
ure, it is necessary to study users of acetaminophen exclu-
sively. Such a population, with no prior use of phenacetin,
may not be possible to identify with confidence for a decade
or longer in the United States, with a shorter period for
those countries that banned phenacetin sooner. Inadequate
adjustment, or lack of adjustment for phenacetin alto-
gether, limits the validity of reported associations between
renal failure and non-phenacetin analgesics in other studies
as well [16, 31, 32]. Residual confounding by phenacetin
use cannot be excluded even in studies which claim to
adjust for it, given that the exposure is self-reported and
subject to major information bias, as described above.
Furthermore, significant differences between cases and
controls were often evident with respect to a number of
variables not accounted for in the analysis. These included
race, sex, proxy response status, use of other medications,
and socioeconomic status, all factors with potential for
aggregate confounding that cannot be discounted on the
basis of single factor evaluation [47]. For instance, in the
study by Murray et al [30], the level of education, a marker
of socioeconomic status, was significantly lower among
cases than among controls and was not accounted for in the
analysis.
Finally, as discussed above, it is necessary to analyze each
type of analgesic in relation to date started and ended and
to identify reasons for discontinuation or switching. For
studies that included cases at various stages of renal failure,
it would be useful to analyze risk associated with analgesic
use by stage of disease. Such detailed analyses of type and
timing of analgesic use have not been presented in any
published study and may be precluded by the small num-
bers of users.
SUMMARY AND RECOMMENDATIONS
As the incidence of chronic renal failure continues to
increase, as indicated by rising ESRD rates, and in the
absence of effective treatment, prevention remains an
important strategy for the control of this disease. The
widespread use of analgesics calls for detailed evaluation of
these drugs as potential risk factors for chronic renal
disease. Several epidemiologic studies have attempted to
examine the association between analgesic use and chronic
renal failure; while the aggregate data suggest a relation
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between heavy habitual use (particularly of products con-
taining phenacetin) and chronic renal failure, the specific
ingredient(s) responsible, as well as the duration of use and
cumulative consumption required to produce the lesion,
are less clear. Furthermore, it is unlikely that this issue can
be resolved through a case-control study of patients late in
the natural history of chronic renal failure. Etiologic infer-
ences that can be drawn from the collective evidence to
date are limited by numerous methodological flaws, the
most serious of which is the inclusion of ESRD patients,
whose patterns and reporting of analgesic use are likely to
be affected by their illness, and by the failure to mutually
adjust for the confounding effects of different analgesics.
The cohort study approach minimizes problems of recall
and several other potential biases, but is difficult to imple-
ment because of the rarity of chronic renal failure in the
general population [3].
In designing future studies of analgesic use and chronic
renal failure, we suggest that the following steps be at-
tempted. (1) Include cases diagnosed at the earliest stage of
disease. This is difficult since little is known about early
stage disease and the identification of such patients [37, 38,
48], although recent work suggests highly predictive diag-
nostic performance of computed tomography scan in early
stage renal failure [49]. Such an approach will minimize
recall or reporting biases due to post-diagnostic changes in
analgesic use patterns or lengthy time periods between
disease diagnosis and interview. (2) Detailed information
should be collected on date started and ended, and reasons
for discontinuation or switching. (3) Interviews should be
conducted in person, with visual aids of analgesic brand
names and packaging if possible. Ideally, one would vali-
date prescription analgesic use data through pharmacy
records, if possible. (4) Population-based studies, with
patients and comparison subjects drawn from the same
source population, are preferable to hospital-based studies.
(5) Finally, the number of study participants should be
large enough to adjust for the mutually confounding effects
of different analgesic types as well as the potential con-
founding effects of other risk factors.
In summary, the case-control studies of analgesic use and
renal failure suffer from serious selection, information and
confounding biases operating in different directions and
generating both false positive and false negative associa-
tions. Thus, while the collective evidence suggests that
habitual analgesic use may be associated with the develop-
ment of chronic renal failure, it does not conclusively
establish a causal link between use of specific analgesics,
particularly acetaminophen, and chronic renal failure.
However, because of the widespread use of analgesics, the
recent introduction of new products, and the potential
impact of these drugs on renal failure, the continued
evaluation of any renal toxicity is a major research and
public health priority.
Reprint requests to Dr. Joseph K. McLaughlin, International Epidemiology
Institute, 1550 Research Blvd., Rockville, Maryland 20850, USA.
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